Trombosis asociada al cáncer (CAT): cambio de paradigma, una revisión de la literatura
KMG Cardenas, DV Martín… - Revista Colombiana de …, 2022 - revistacancercol.org
La trombosis asociada al cáncer es una de las principales causas de morbimortalidad en
los pacientes oncológicos; tiene una incidencia de 13.9 por 1000 personas año …
los pacientes oncológicos; tiene una incidencia de 13.9 por 1000 personas año …
Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus
Management of anticoagulant therapy for the treatment of venous thromboembolism (VTE)
in cancer patients is complex because of an increased risk of recurrent VTE and major …
in cancer patients is complex because of an increased risk of recurrent VTE and major …
Cancer thrombosis: Narrative review
Venous thromboembolism (VTE) is a common disease in patients with cancer and carries a
poor prognosis. Although the exact incidence of VTE in patients with cancer lies between …
poor prognosis. Although the exact incidence of VTE in patients with cancer lies between …
Tromboembolismo en pacientes oncológicos
RC Morales Luzuriaga - 2023 - repositorio.uta.edu.ec
Introducción: Los pacientes con cáncer activo tienen un mayor riesgo de desarrollar
tromboembolismo venoso, lo que puede conducir a una morbilidad, mortalidad y costos de …
tromboembolismo venoso, lo que puede conducir a una morbilidad, mortalidad y costos de …
Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients' …
A Muñoz Martín, AJ Trujillo-Santos, E Martí… - Clinical and …, 2024 - Springer
Cancer patients are at risk of venous thromboembolism (VTE), its recurrence, but also at risk
of bleeding while anticoagulated. In addition, cancer therapies have been associated to …
of bleeding while anticoagulated. In addition, cancer therapies have been associated to …
Approach to cancer‐associated thrombosis: challenging situations and knowledge gaps
TF Wang, HH Billett, JM Connors, GA Soff - The Oncologist, 2021 - academic.oup.com
Malignancy is a significant risk factor for venous thromboembolism (VTE). It is estimated that
up to 20% of patients with cancer may develop VTE at some time in their cancer journey …
up to 20% of patients with cancer may develop VTE at some time in their cancer journey …
Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations
M Carrier, A Lazo-Langner, S Shivakumar… - Current …, 2015 - mdpi.com
Venous thromboembolism is a common complication in cancer patients, and
thromboembolism is the second most common cause of death after cancer progression. A …
thromboembolism is the second most common cause of death after cancer progression. A …
[HTML][HTML] Trombosis asociada a cáncer (TAC). Nuevos desafíos para el hematólogo.
AJ Maneyro - Hematologia: Volumen 23-Extraordinario XXIV …, 2019 - books.google.com
La relación entre el cáncer y el tromboembolismo venoso (TEV) es conocida desde hace
casi dos siglos; desde las descripciones iniciales de Bouillard y Trousseau (1, 2), múltiples …
casi dos siglos; desde las descripciones iniciales de Bouillard y Trousseau (1, 2), múltiples …
Controversies in the management of cancer-associated thrombosis
M Carrier, P Prandoni - Expert Review of Hematology, 2017 - Taylor & Francis
Introduction: Cancer associated thrombosis (CAT) is a frequent complication among cancer
patients. It is associated with increased morbidity, mortality, and psychological burden …
patients. It is associated with increased morbidity, mortality, and psychological burden …
Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis
Updated clinical practice guidelines recommend the long-term use of low-molecular-weight
heparins or direct oral anticoagulants as the preferred option for the treatment of cancer …
heparins or direct oral anticoagulants as the preferred option for the treatment of cancer …